New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension

New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up. […]

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension Read Post »

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026

Researchers from China have traced the remarkable 30-year evolution of pulmonary arterial hypertension treatment, from a disease with no effective options to one on the cusp of a potential cure. What was once described as the “cancer of cardiovascular diseases” — with a median survival of just 2.8 years after diagnosis — has become a

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026 Read Post »

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026

New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat. The analysis combined data from three phase

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026 Read Post »

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026

A 10-week fully remote, home-based exercise programme for people with pulmonary hypertension (pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) was found to be both acceptable and beneficial, according to a study conducted by a group of Irish researchers, based on qualitative interviews with 13 participants. The programme combined aerobic, resistance and respiratory

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026

Researchers from Canada have published a review which summarizes recently established and emerging signalling pathways that may influence the next generation of targeted pulmonary arterial hypertension therapies. They note that the therapeutic landscape for this condition is moving towards mechanism-based approaches with the potential to alter the course of the disease. In particular, the transforming

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026 Read Post »

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026

Assessment of exercise provides important prognostic information about pulmonary arterial hypertension patients. Researchers from the UK have recently published a review of current digital alternatives to traditional outcome measures. The 6-minute walk test (6MWT) is a key tool for monitoring pulmonary arterial hypertension, but since care is often centralized, patients may only do it once

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026 Read Post »

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026

The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. A systematic review published on April 13, 2026 on Health Quality of Life Outcomes has synthesized the available evidence on the impact of pulmonary arterial hypertension on patients’ QoL measured by PROMs.

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026 Read Post »

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026

The right heart catheter – also known as cardiac catheterisation, and abbreviated as RHC –is considered the “gold standard’ test to diagnose pulmonary arterial hypertension, and at follow up to monitor progress of the condition and efficacy of treatments. In this video Dr Charlie Elliott, from the Sheffield Pulmonary Vascular Disease Unit, who has performed

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026 Read Post »

Study suggests that pulmonary arterial hypertension extends beyond the cardiopulmonary system to affect brain structure and memory, Nature Scientific reports, April 3, 2026

Patients with pulmonary arterial hypertension often present neuropsychological symptoms, which suggest central nervous system involvement. A study conducted on rats with experimentally induced pulmonary arterial hypertension, recently published on Nature Scientific Reports showed reduced exploratory activity and cognitive impairment, alongside neuroinflammation in the cortex and hippocampus, disruption of the blood-brain barrier and elevated inflammatory markers.

Study suggests that pulmonary arterial hypertension extends beyond the cardiopulmonary system to affect brain structure and memory, Nature Scientific reports, April 3, 2026 Read Post »

New blood markers show promise for World Health Organisation (WHO) Group 2 pulmonary hypertension, Pulmonary Hypertension News, March 23, 2026

Pulmonary Hypertension News has recently reported on a small Chinese study exploring whether microRNAs — tiny molecules found in the blood that help regulate gene activity — could serve as non-invasive diagnostic markers for World Health Organisation (WHO) Group 2 pulmonary hypertension (pulmonary hypertension caused by left heart disease), potentially offering an alternative to the

New blood markers show promise for World Health Organisation (WHO) Group 2 pulmonary hypertension, Pulmonary Hypertension News, March 23, 2026 Read Post »

Congenital Heart Disease and Pulmonary Arterial Hypertension: Current Perspectives, Review of Cardiovascular Medicine, March 20, 2026

A comprehensive review recently published in the Review of Cardiovascular Medicine covers the epidemiology, pathophysiology, diagnosis and management of pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), a heterogeneous and serious condition accounting for up to one third of all pulmonary arterial hypertension cases in adults. Key topics include the updated 2022 European Society

Congenital Heart Disease and Pulmonary Arterial Hypertension: Current Perspectives, Review of Cardiovascular Medicine, March 20, 2026 Read Post »

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026

To date sotatercept has only been studied in patients with prevalent pulmonary arterial hypertension receiving stable background therapy, not as part of the initial treatment regimen in newly diagnosed patients. A case report, published recently on the ERJ Open Research, describes a 25-year-old woman who developed severe high-risk idiopathic pulmonary arterial hypertension (IPAH) shortly after

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026 Read Post »

René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research

At the 66th Congress of the German Society for Pneumology in Munich, the €5,000 René Baumgart Foundation research prize was awarded to two outstanding researchers working in the field of pulmonary hypertension (full text in German available at this link) English AI translation and summary Dr. Fenja Knöpp (Justus Liebig University, Giessen) was recognised for

René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research Read Post »

Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), an European Society of Cardiology (ESC) scientific statement, European Journal of Heart Failure, March 9, 2026

A scientific statement of the European Society of Cardiology Working Group on Pulmonary Circulation & Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease (PAH-CHD), and the Association of Cardiovascular Nursing & Allied Professions of the ESC was recently published in the European Journal of Heart Failure. The authors say that current

Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), an European Society of Cardiology (ESC) scientific statement, European Journal of Heart Failure, March 9, 2026 Read Post »

Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension, NPJ Vascular Health, March 25, 2026

A UK pilot study explored whether physical activity data from wearable devices and a smartphone app (My Heart Counts) could help detect idiopathic pulmonary arterial hypertension (IPAH) earlier, before formal diagnosis. Analysing up to eight years of real-world activity and heart rate data from 109 participants, including patients with idiopathic pulmonary arterial hypertension, disease controls,

Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension, NPJ Vascular Health, March 25, 2026 Read Post »

Defining quality standards of care in Connective Tissue Disease-Pulmonary Arterial Hypertension (CTD-PAH) and management best practices: a Delphi panel consensus, Rheumatology Advances in Practice, January 2026

A European Delphi panel involving 24 healthcare professionals from six countries reached consensus on best practices for managing pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly systemic sclerosis (SSc). Key areas of agreement included the importance of multimodal screening combining echocardiography, biomarkers and symptom evaluation, better access to echocardiography, and a multidisciplinary approach

Defining quality standards of care in Connective Tissue Disease-Pulmonary Arterial Hypertension (CTD-PAH) and management best practices: a Delphi panel consensus, Rheumatology Advances in Practice, January 2026 Read Post »

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026

Exposure to cigarette smoke is a well-recognised risk factor for endothelial dysfunction, which causes changes in pulmonary vascular architecture and can lead to pulmonary hypertension — and notably, these changes occur at an early stage of smoking-related lung disease, long before airway obstruction develops. Despite this, the specific impact of smoking on pulmonary arterial hypertension

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026 Read Post »

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026

Since sotatercept received Food and Drug Administration (FDA) approval for pulmonary arterial hypertension in March 2024, knowing when and how to use it has become an essential part of managing this serious condition — so say the authors of a recently published article in CHEST, who offer a practical guide for clinicians navigating this new

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026 Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

TRANSLATE »
Scroll to Top